Чехия - чешки - SUKL (Státní ústav pro kontrolu léčiv)

stada arzneimittel ag, bad vilbel array - 16227 ezetimib; 14884 trihydrÁt vÁpenatÉ soli atorvastatinu - potahovaná tableta - 10mg/40mg - atorvastatin a ezetimib

Чехия - чешки - SUKL (Státní ústav pro kontrolu léčiv)

stada arzneimittel ag, bad vilbel array - 16227 ezetimib; 14884 trihydrÁt vÁpenatÉ soli atorvastatinu - potahovaná tableta - 10mg/80mg - atorvastatin a ezetimib

Европейски съюз - чешки - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastická činidla - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 a 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

Европейски съюз - чешки - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - karcinom, skvamózní buňka - antineoplastická činidla - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Чехия - чешки - SUKL (Státní ústav pro kontrolu léčiv)

actavis group ptc ehf., hafnarfjördur array - 17338 atomoxetin-hydrochlorid - tvrdá tobolka - 10mg - atomoxetin

Чехия - чешки - SUKL (Státní ústav pro kontrolu léčiv)

actavis group ptc ehf., hafnarfjördur array - 17338 atomoxetin-hydrochlorid - tvrdá tobolka - 100mg - atomoxetin

Чехия - чешки - SUKL (Státní ústav pro kontrolu léčiv)

actavis group ptc ehf., hafnarfjördur array - 17338 atomoxetin-hydrochlorid - tvrdá tobolka - 18mg - atomoxetin

Чехия - чешки - SUKL (Státní ústav pro kontrolu léčiv)

actavis group ptc ehf., hafnarfjördur array - 17338 atomoxetin-hydrochlorid - tvrdá tobolka - 25mg - atomoxetin

Чехия - чешки - SUKL (Státní ústav pro kontrolu léčiv)

actavis group ptc ehf., hafnarfjördur array - 17338 atomoxetin-hydrochlorid - tvrdá tobolka - 40mg - atomoxetin

Чехия - чешки - SUKL (Státní ústav pro kontrolu léčiv)

actavis group ptc ehf., hafnarfjördur array - 17338 atomoxetin-hydrochlorid - tvrdá tobolka - 60mg - atomoxetin